Daunorubicin

Generic Name: Daunorubicin

Brand Names: Cerubidine, Vyxeos

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₂₉NO_₁₀

CAS Number: 20830-81-3

Unique Ingredient Identifier: ZS7284E0ZP

Background: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.

Indication: For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.
...

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Chronic Phase Chronic Myeloid Leukemia, Ewing's Sarcoma, Lymphoma, Diffuse, Myeloblastic Leukemia, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Wilms' tumor

Associated Therapies: -

Clinical Trials

Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics

Phase 3

Recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: CPX-351
Drug: Cytarabine
Drug: Daunorubicin

First Posted Date: 2019-04-01

Last Posted Date: 2024-11-06

Lead Sponsor: University of Ulm

Target Recruit Count: 882

Registration Number: NCT03897127

Locations: 🇩🇪
Klinikum Bremen-Mitte, Bremen, Germany
🇩🇪
Klinikum Darmstadt, Darmstadt, Germany
🇩🇪
St.-Johannes-Hospital, Dortmund, Germany

and more 61 locations

A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Idasanutlin
Drug: Cytarabine
Drug: Daunorubicin
Procedure: Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)

First Posted Date: 2019-02-21

Last Posted Date: 2022-06-21

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 24

Registration Number: NCT03850535

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸
UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

and more 23 locations

Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

Phase 2

Active, not recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Gilteritinib
Drug: Midostaurin
Drug: Daunorubicin
Drug: Cytarabine

First Posted Date: 2019-02-11

Last Posted Date: 2024-02-22

Lead Sponsor: PrECOG, LLC.

Target Recruit Count: 181

Registration Number: NCT03836209

Locations: 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States

and more 41 locations

Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Cytarabine
Drug: Daunorubicin
Drug: Daunorubicin Hydrochloride
Drug: Pinometostat

First Posted Date: 2018-10-30

Last Posted Date: 2024-06-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 6

Registration Number: NCT03724084

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
Yale University, New Haven, Connecticut, United States

Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Venetoclax
Drug: Daunorubicin
Drug: Cytarabine

First Posted Date: 2018-10-17

Last Posted Date: 2024-08-15

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 64

Registration Number: NCT03709758

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

Phase 2

Active, not recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Drug: Cytarabine
Drug: Daunorubicin
Procedure: Echocardiography
Procedure: Multigated Acquisition Scan
Drug: Uproleselan

First Posted Date: 2018-10-10

Last Posted Date: 2024-12-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 670

Registration Number: NCT03701308

Locations: 🇺🇸
Mercy Health - Perrysburg Hospital, Perrysburg, Ohio, United States
🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸
Community Cancer Institute, Clovis, California, United States

and more 185 locations

Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

First Posted Date: 2018-08-22

Last Posted Date: 2023-11-29

Lead Sponsor: Martin Schrappe

Target Recruit Count: 5000

Registration Number: NCT03643276

Locations: 🇮🇹
AOUC Policlinico Bari, Bari, Italy
🇮🇹
A.O. Papa Giovanni XXIII, Bergamo, Italy
🇮🇹
S.O. Annunziata - A. O. Cosenza, Cosenza, Italy

and more 111 locations

Atovaquone (Mepron®) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML)

Early Phase 1

Active, not recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Atovaquone
Drug: Cytarabine
Drug: Daunorubicin
Drug: Etoposide
Drug: Gemtuzumab Ozogamicin

First Posted Date: 2018-06-26

Last Posted Date: 2024-11-21

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 26

Registration Number: NCT03568994

Locations: 🇺🇸
Baylor College of Medicine - Texas Childrens Hospital, Houston, Texas, United States
🇺🇸
Johns Hopkins Medicine, Baltimore, Maryland, United States

A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Alvocidib
Drug: Cytarabine
Drug: Mitoxantrone
Drug: Daunorubicine

First Posted Date: 2018-06-20

Last Posted Date: 2022-04-12

Lead Sponsor: Sumitomo Pharma Co., Ltd.

Target Recruit Count: 10

Registration Number: NCT03563560

Locations: 🇯🇵
Fukui University Hospital, Yoshida-gun, Fukui, Japan
🇯🇵
Chugoku Central Hospital, Fukuyama, Hiroshima, Japan
🇯🇵
Hokkaido University Hospital, Sapporo, Hokkaido, Japan

and more 8 locations

Epacadostat, Idarubicin and Cytarabine (EIC) in AML

Phase 1

Withdrawn

Conditions: AML

Interventions: Drug: Epacadostat
Drug: Idarubicin
Drug: Cytarabine
Drug: Daunorubicin

First Posted Date: 2018-02-23

Last Posted Date: 2018-09-11

Lead Sponsor: Insel Gruppe AG, University Hospital Bern

Registration Number: NCT03444649

Locations: 🇨🇭
Departement of Medical Oncology, University Hospital Berne, Berne, Switzerland

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy